BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12838937)

  • 1. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.
    Dörffel W; Lüders H; Rühl U; Albrecht M; Marciniak H; Parwaresch R; Pötter R; Schellong G; Schwarze EW; Wickmann L
    Klin Padiatr; 2003; 215(3):139-45. PubMed ID: 12838937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years].
    Dörffel W; Albrecht M; Lüders H; Marciniak H; Parwaresch R; Schwarze EW; Trauzeddel R; Havers W; Henze G; Janka-Schaub G; Mann G; Niemeyer C; Pötter R; Schellong G; Selle B; Treuner J; Rühl U
    Klin Padiatr; 1998; 210(4):212-9. PubMed ID: 9743955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
    Schellong G; Pötter R; Brämswig J; Wagner W; Prott FJ; Dörffel W; Körholz D; Mann G; Rath B; Reiter A; Weissbach G; Riepenhausen M; Thiemann M; Schwarze EW
    J Clin Oncol; 1999 Dec; 17(12):3736-44. PubMed ID: 10577845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group.
    Schellong G
    Ann Oncol; 1996; 7 Suppl 4():67-72. PubMed ID: 8836413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90.
    Dieckmann K; Pötter R; Wagner W; Prott FJ; Hörnig-Franz I; Rath B; Schellong G
    Radiother Oncol; 2002 Feb; 62(2):191-200. PubMed ID: 11937246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Hodgkin's disease: treatment in the late 1990s.
    Schellong G
    Ann Oncol; 1998; 9 Suppl 5():S115-9. PubMed ID: 9926249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
    Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
    J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group.
    Schellong G
    Baillieres Clin Haematol; 1996 Sep; 9(3):619-34. PubMed ID: 8922249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
    Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G
    J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
    Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
    Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
    Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk KP; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M
    Blood; 1998 Dec; 92(12):4560-7. PubMed ID: 9845521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of procarbazine in the chemotherapy of Hodgkin's disease--a report of the Cooperative Therapy Study DAL-HD-85].
    Schellong G; Hörnig I; Brämswig J; Bökkerink JP; Steinhoff A; Ludwig R; Niethammer D; Reiter A; von Lengerke HJ; Heinecke H
    Klin Padiatr; 1988; 200(3):205-13. PubMed ID: 3062257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group.
    Schellong G; Brämswig JH; Hörnig-Franz I; Schwarze EW; Pötter R; Wannenmacher M
    Ann Oncol; 1994; 5 Suppl 2():113-5. PubMed ID: 8204510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82].
    Schellong G; Brämswig J; Ludwig R; Gerein V; Jobke A; Jürgens H; Kabisch H; Stollmann B; Weinel P; Gadner H
    Klin Padiatr; 1986; 198(3):137-46. PubMed ID: 3523020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial.
    Rühl U; Albrecht M; Dieckmann K; Lüders H; Marciniak H; Schellenberg D; Wickmann L; Dörffel W
    Int J Radiat Oncol Biol Phys; 2001 Dec; 51(5):1209-18. PubMed ID: 11728679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
    Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
    Ann Oncol; 2005 Dec; 16(12):1936-40. PubMed ID: 16157620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
    Hamilton VM; Norris C; Bunin N; Goldwein JW; Bunin GR; Lange B; Meadows AT
    J Pediatr Hematol Oncol; 2001 Feb; 23(2):84-8. PubMed ID: 11216711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.